Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33713 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL2534896 | 0.89 | CA1 (0.50) | CA1CA2PDE10AALDH1A1CASP1 | |
| SCHEMBL29619760 | 0.76 | — | — | |
| SCHEMBL185204 | 0.76 | — | — | |
| SCHEMBL28865604 | 0.75 | MAPT (0.61) | CA1CA2CA3CA6CA14 | |
| SCHEMBL8466839 | 0.75 | MAPT (0.61) | CA1CA2CA3CA6CA14 | |
| SCHEMBL3199 | 0.75 | — | — | |
| SCHEMBL18867937 | 0.75 | — | — | |
| SCHEMBL6573823 | 0.75 | PDE10A (0.47) | CA1CA2PDE10AALDH1A1CASP1 | |
| 3-Aminophenol SCHEMBL28161683 | 0.75 | ALDH1A1 (0.61) | CA1CA2CA3CA6CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CA1 3329/4885CA2 1724/4885PDE10A 1426/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885PDE10A 1725/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | CA1 3329/4885CA2 1724/4885PDE10A 1426/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885PDE10A 1725/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | CA1 3144/4885CA2 1932/4885PDE10A 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.